Literature DB >> 28498368

It is a differentiation game: STAT5 in a new role.

Barbara Maurer1,2, Matthias Farlik3, Veronika Sexl4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28498368      PMCID： PMC5442481          DOI： 10.1038/cdd.2017.71

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  13 in total

1.  Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells.

Authors:  Matthew A Burchill; Christine A Goetz; Martin Prlic; Jennifer J O'Neil; Ian R Harmon; Steven J Bensinger; Laurence A Turka; Paul Brennan; Stephen C Jameson; Michael A Farrar
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

2.  High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

Authors:  Wolfgang Warsch; Karoline Kollmann; Eva Eckelhart; Sabine Fajmann; Sabine Cerny-Reiterer; Andrea Hölbl; Karoline V Gleixner; Michael Dworzak; Matthias Mayerhofer; Gregor Hoermann; Harald Herrmann; Christian Sillaber; Gerda Egger; Peter Valent; Richard Moriggl; Veronika Sexl
Journal:  Blood       Date:  2011-01-10       Impact factor: 22.113

3.  STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion.

Authors:  Dagmar Gotthardt; Eva M Putz; Eva Grundschober; Michaela Prchal-Murphy; Elisabeth Straka; Petra Kudweis; Gerwin Heller; Zsuzsanna Bago-Horvath; Agnieszka Witalisz-Siepracka; Abbarna A Cumaraswamy; Patrick T Gunning; Birgit Strobl; Mathias Müller; Richard Moriggl; Christian Stockmann; Veronika Sexl
Journal:  Cancer Discov       Date:  2016-02-12       Impact factor: 39.397

4.  Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.

Authors:  Christoph Walz; Wesam Ahmed; Katherine Lazarides; Monica Betancur; Nihal Patel; Lothar Hennighausen; Virginia M Zaleskas; Richard A Van Etten
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

5.  Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.

Authors:  Andrea Hoelbl; Christian Schuster; Boris Kovacic; Bingmei Zhu; Mark Wickre; Maria A Hoelzl; Sabine Fajmann; Florian Grebien; Wolfgang Warsch; Gabriele Stengl; Lothar Hennighausen; Valeria Poli; Hartmut Beug; Richard Moriggl; Veronika Sexl
Journal:  EMBO Mol Med       Date:  2010-03       Impact factor: 12.137

6.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Authors:  Kathryn G Roberts; Yongjin Li; Debbie Payne-Turner; Richard C Harvey; Yung-Li Yang; Deqing Pei; Kelly McCastlain; Li Ding; Charles Lu; Guangchun Song; Jing Ma; Jared Becksfort; Michael Rusch; Shann-Ching Chen; John Easton; Jinjun Cheng; Kristy Boggs; Natalia Santiago-Morales; Ilaria Iacobucci; Robert S Fulton; Ji Wen; Marcus Valentine; Cheng Cheng; Steven W Paugh; Meenakshi Devidas; I-Ming Chen; Shalini Reshmi; Amy Smith; Erin Hedlund; Pankaj Gupta; Panduka Nagahawatte; Gang Wu; Xiang Chen; Donald Yergeau; Bhavin Vadodaria; Heather Mulder; Naomi J Winick; Eric C Larsen; William L Carroll; Nyla A Heerema; Andrew J Carroll; Guy Grayson; Sarah K Tasian; Andrew S Moore; Frank Keller; Melissa Frei-Jones; James A Whitlock; Elizabeth A Raetz; Deborah L White; Timothy P Hughes; Jaime M Guidry Auvil; Malcolm A Smith; Guido Marcucci; Clara D Bloomfield; Krzysztof Mrózek; Jessica Kohlschmidt; Wendy Stock; Steven M Kornblau; Marina Konopleva; Elisabeth Paietta; Ching-Hon Pui; Sima Jeha; Mary V Relling; William E Evans; Daniela S Gerhard; Julie M Gastier-Foster; Elaine Mardis; Richard K Wilson; Mignon L Loh; James R Downing; Stephen P Hunger; Cheryl L Willman; Jinghui Zhang; Charles G Mullighan
Journal:  N Engl J Med       Date:  2014-09-11       Impact factor: 91.245

7.  Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.

Authors:  Lynn M Heltemes-Harris; Mark J L Willette; Laura B Ramsey; Yi Hua Qiu; E Shannon Neeley; Nianxiang Zhang; Deborah A Thomas; Thearith Koeuth; Emily C Baechler; Steven M Kornblau; Michael A Farrar
Journal:  J Exp Med       Date:  2011-05-23       Impact factor: 14.307

8.  Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.

Authors:  Andrea Hoelbl; Boris Kovacic; Marc A Kerenyi; Olivia Simma; Wolfgang Warsch; Yongzhi Cui; Hartmut Beug; Lothar Hennighausen; Richard Moriggl; Veronika Sexl
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

9.  Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia.

Authors:  Grace J Liu; Luisa Cimmino; Julian G Jude; Yifang Hu; Matthew T Witkowski; Mark D McKenzie; Mutlu Kartal-Kaess; Sarah A Best; Laura Tuohey; Yang Liao; Wei Shi; Charles G Mullighan; Michael A Farrar; Stephen L Nutt; Gordon K Smyth; Johannes Zuber; Ross A Dickins
Journal:  Genes Dev       Date:  2014-06-15       Impact factor: 11.361

10.  Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia.

Authors:  L M Heltemes-Harris; J D Larson; T K Starr; G K Hubbard; A L Sarver; D A Largaespada; M A Farrar
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867
View more
  2 in total

Review 1.  Balancing STAT Activity as a Therapeutic Strategy.

Authors:  Kelsey L Polak; Noah M Chernosky; Jacob M Smigiel; Ilaria Tamagno; Mark W Jackson
Journal:  Cancers (Basel)       Date:  2019-11-03       Impact factor: 6.575

2.  Valproic Acid Suppresses Autoimmune Recurrence and Allograft Rejection in Islet Transplantation through Induction of the Differentiation of Regulatory T Cells and Can Be Used in Cell Therapy for Type 1 Diabetes.

Authors:  Jeng-Rong Lin; Shing-Hwa Huang; Chih-Hsiung Wu; Yuan-Wu Chen; Zhi-Jie Hong; Chia-Pi Cheng; Huey-Kang Sytwu; Gu-Jiun Lin
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.